journal article·2026-03-13Open access

Bibliometric and visualized analysis of nanomedicine research trends for gastric cancer during the early 21st century

Xuanwei Huang, Linpo Zhou, Yuqiang Shan

Discover Nano· Volume 21· Issue 1

Abstract

Gastric cancer (GC) remains a leading cause of cancer-related morbidity and mortality worldwide, particularly in East Asia. Nanomedicine has emerged as a promising strategy to enhance the precision and efficacy of GC diagnosis and therapy. This study aimed to systematically evaluate global research trends and knowledge structures in GC nanomedicine during the early 21st century using bibliometric and visualization analyses. Relevant publications during the early 21st century were retrieved from the Web of Science Core Collection (WoSCC) and analyzed using R, VOSviewer, CiteSpace, Scimago Graphica, and Pajek. The included records spanned 2003-2026, with the two items labeled "2026" reflecting early access articles already indexed in WoSCC at the time of data retrieval. A total of 1,717 publications authored by 9,857 researchers across 2,192 institutions in 83 countries were included. China, Iran, and the United States were identified as leading contributors, with major research hubs at the Chinese Academy of Sciences, Shanghai Jiao Tong University, and Islamic Azad University. Research output exhibited a sustained upward trend, with citation frequency and H-index steadily increasing. Five primary research hotspots were identified: nano-drug delivery and chemotherapy optimization, targeted therapy and signaling pathway modulation, photothermal/photodynamic synergistic therapies, functionalized nanomaterials for diagnostics, and immunotherapeutic/antibacterial nanomedicine. Over time, the field has evolved from early nanocarrier design (2003-2015) to targeted therapy and diagnostic applications (2015-2020), and more recently toward immunotherapy and green synthesis strategies (2020-2026). Importantly, most studies in this field remain at the preclinical or early translational stage, underscoring the need for further validation using standardized preclinical models and well-designed clinical trials. This bibliometric study provides a comprehensive overview of the developmental trajectory, key contributors, and emerging trends in GC nanomedicine, offering valuable insights to guide future interdisciplinary research, clinical translation, and strategic resource allocation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Diverse Scientific Research Studies · Gastric Cancer Management and Outcomes · Cancer Research and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (74)

Show source-provided references
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. 21834. PubMed PMID: 38572751.
2. Qin N, Fan Y, Yang T, Yang Z, Fan D. The burden of Gastric Cancer and possible risk factors from 1990 to 2021, and projections until 2035: findings from the Global Burden of Disease Study 2021. Biomark Res. 2025;13(1):5. https://doi.org/10.1186/s40364-024-00720-8.10.1186/s40364-024-00720-8 ↗
3. Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Oncol. 2022;125(7):1104–9. 10.1002. /jso.26844. PubMed PMID: 35481909; PubMed Central PMCID: PMC9322671.10.1002/jso.26844 ↗
4. Yuan X, Chen C, Pang Y, Wang X, Yang T, Long A, et al. Multimodal therapeutic strategies against gastric cancer: from conventional treatments to tumor microenvironment targeting. Front Immunol. 2025;16:1623588. https://doi.org/10.3389/fimmu.2025.1623588. Epub 20250904.10.3389/fimmu.2025.1623588 ↗
5. Panahizadeh R, Panahi P, Asghariazar V, Makaremi S, Noorkhajavi G, Safarzadeh E. A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies. Cancer Cell Int. 2025;25(1):23. https://doi.org/10.1186/s12935-025-03655-8.10.1186/s12935-025-03655-8 ↗
6. Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022;12:960317. https://doi.org/10.3389/fonc.2022.960317. Epub 20220729.10.3389/fonc.2022.960317 ↗
7. Radford M, Abushukair H, Hentzen S, Cavalcante L, Saeed A. Targeted and immunotherapy approaches in HER2-positive gastric and gastroesophageal junction adenocarcinoma: a new era. J Immunother Precis Oncol. 2023;6(3):150–7. https://doi.org/10.36401/jipo-22-36. Epub 20230622.10.36401/jipo-22-36 ↗
8. Akkanapally V, Bai XF, Basu S. Therapeutic Immunomodulation in Gastric Cancer. Cancers (Basel). 2024;16(3). Epub 20240128. doi: 10.3390/cancers16030560. PubMed PMID: 38339311; PubMed Central PMCID: PMC10854796.10.3390/cancers16030560 ↗
9. Li X, Ai S, Lu X, Liu S, Guan W. Nanotechnology-based strategies for gastric cancer imaging and treatment. RSC Adv. 2021;11(56):35392–407. https://doi.org/10.1039/d1ra01947c. Epub 20211102.10.1039/d1ra01947c ↗
10. Wang S, Li J, Zhang Z, Cao S, Zhang Z, Bian Y, et al. Advances in nanomedicine and delivery systems for gastric cancer research. Front Bioeng Biotechnol. 2025;13:1565999. https://doi.org/10.3389/fbioe.2025.1565999. Epub 20250321.10.3389/fbioe.2025.1565999 ↗
11. Yang T, Guo L. Advancing gastric cancer treatment: nanotechnology innovations and future prospects. Cell Biol Toxicol. 2024;40(1):101. Epub 20241120. doi: 10.1007/s10565-024-09943-9. PubMed PMID: 39565472; PubMed Central PMCID: PMC11579161.10.1007/s10565-024-09943-9 ↗
12. Hani U, Osmani RAM, Yasmin S, Gowda BHJ, Ather H, Ansari MY et al. Novel drug delivery systems as an emerging platform for stomach cancer therapy. Pharmaceutics. 2022;14(8). Epub 20220729. https://doi.org/10.3390/pharmaceutics14081576. PubMed PMID: 36015202; PubMed Central PMCID: PMC9416534.10.3390/pharmaceutics14081576 ↗
13. Fang X, Lan H, Jin K, Gong D, Qian J. Nanovaccines for cancer prevention and immunotherapy: an update review. Cancers (Basel). 2022;14(16). Epub 20220809. https://doi.org/10.3390/cancers14163842. PubMed PMID: 36010836; PubMed Central PMCID: PMC9405528.10.3390/cancers14163842 ↗
14. Zhou L, Huang X, Shi J, Yang Y, Dong F, Wei H, et al. Decoding colorectal cancer targeted therapy: a bibliometric journey of the last decade (2015–2024). Discov Oncol. 2025;16(1):442. https://doi.org/10.1007/s12672-025-02251-6. Epub 20250401.10.1007/s12672-025-02251-6 ↗
15. Bakkalbasi N, Bauer K, Glover J, Wang L. Three options for citation tracking: google scholar, scopus and web of science. Biomed Digit Libr. 2006;3:7. https://doi.org/10.1186/1742-5581-3-7. Epub 20060629.10.1186/1742-5581-3-7 ↗
16. Birkle C, Pendlebury DA, Schnell J, Adams J. Web of Science as a data source for research on scientific and scholarly activity. Quant Sci Stud. 2020;1(1):363–76.10.1162/qss_a_00018 ↗
17. Gregorio-Chaviano O, López Mesa EK, Limaymanta CH. Web of Science as a research tool and support for scientific activity: lights and shadows of their collections, products and indicators. E-Ciencias de la Información. 2022;12(1):134–57.
18. Sweileh WM. Global research activity on antimicrobial resistance in food-producing animals. Arch Public Health. 2021;79(1):49. Epub 20210413. doi: 10.1186/s13690-021-00572-w. PubMed PMID: 33849636; PubMed Central PMCID: PMC8045364.10.1186/s13690-021-00572-w ↗
19. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. https://doi.org/10.1007/s11192-009-0146-3. Epub 20091231.10.1007/s11192-009-0146-3 ↗
20. Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS ONE. 2019;14(10):e0223994. https://doi.org/10.1371/journal.pone.0223994. Epub 20191031.10.1371/journal.pone.0223994 ↗
21. Hassan-Montero Y, De-Moya-Anegón F, Guerrero-Bote VP. SCImago Graphica: a new tool for exploring and visually communicating data. Profesional de la información. 2022;31(5).10.3145/epi.2022.sep.02 ↗
22. Erratum. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4):313. https://doi.org/10.3322/caac.21609.10.3322/caac.21609 ↗
23. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.10.3322/caac.21660 ↗
24. Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42. https://doi.org/10.1016/j.cgh.2019.07.045.10.1016/j.cgh.2019.07.045 ↗
25. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.10.3322/caac.21834 ↗
26. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.10.3322/caac.21338 ↗
27. Li S, Liu H, Jia Y, Deng Y, Zhang L, Lu Z, He N. A novel SNPs detection method based on gold magnetic nanoparticles array and single base extension. Theranostics. 2012;2(10):967–75. https://doi.org/10.7150/thno.5032. Epub 20121009.10.7150/thno.5032 ↗
28. Ma C, Li C, Wang F, Ma N, Li X, Li Z, et al. Magnetic nanoparticles-based extraction and verification of nucleic acids from different sources. J Biomed Nanotechnol. 2013;9(4):703–9. https://doi.org/10.1166/jbn.2013.1566. PubMed PMID: 23621032.10.1166/jbn.2013.1566 ↗
29. Jiang H, Zeng X, Xi Z, Liu M, Li C, Li Z, et al. Improvement on controllable fabrication of streptavidin-modified three-layer core-shell Fe3O4@SiO2@Au magnetic nanocomposites with low fluorescence background. J Biomed Nanotechnol. 2013;9(4):674–84. https://doi.org/10.1166/jbn.2013.1575. PubMed PMID: 23621028.10.1166/jbn.2013.1575 ↗
30. Tang Y, Ali Z, Zou J, Yang K, Mou X, Li Z, et al. Detection of pseudomonas aeruginosa based on magnetic enrichment and nested PCR. J Nanosci Nanotechnol. 2014;14(7):4886–90. https://doi.org/10.1166/jnn.2014.8707.10.1166/jnn.2014.8707 ↗
31. Liu M, Hu P, Zhang G, Zeng Y, Yang H, Fan J, et al. Copy number variation analysis by ligation-dependent PCR based on magnetic nanoparticles and chemiluminescence. Theranostics. 2015;5(1):71–85. https://doi.org/10.7150/thno.10117.10.7150/thno.10117 ↗
32. Huang R, Xi Z, He N. Applications of aptamers for chemistry analysis, medicine and food security. Sci China Chem. 2015;58(7):1122–30. https://doi.org/10.1007/s11426-015-5344-7.10.1007/s11426-015-5344-7 ↗
33. Wang J, Ali Z, Wang N, Liang W, Liu H, Li F, et al. Simultaneous extraction of DNA and RNA from Escherichia coli BL 21 based on silica-coated magnetic nanoparticles. Sci China Chem. 2015;58(11):1774–8. https://doi.org/10.1007/s11426-015-5483-x.10.1007/s11426-015-5483-x ↗
34. Liu Y, Liu K, Dong H, Zhang L, Deng Y, Ma C, Wang Z. Acetylcholinesterase biosensor for carbaryl detection based on nano-porous pseudo carbon paste electrode. Nanosci Nanatechnol Lett. 2016;8(9):785–90. https://doi.org/10.1166/nnl.2016.2264.10.1166/nnl.2016.2264 ↗
35. Ali Z, Wang J, Tang Y, Liu B, He N, Li Z. Simultaneous detection of multiple viruses based on chemiluminescence and magnetic separation. Biomater Sci. 2016;5(1):57–66. https://doi.org/10.1039/c6bm00527f. PubMed PMID: 27845789.10.1039/c6bm00527f ↗
36. Liu Y, Deng Y, Dong H, Liu K, He N. Progress on sensors based on nanomaterials for rapid detection of heavy metal ions. Sci China Chem. 2017;60(3):329–37. https://doi.org/10.1007/s11426-016-0253-2.10.1007/s11426-016-0253-2 ↗
37. Yi H, Ur Rehman F, Zhao C, Liu B, He N. Recent advances in nano scaffolds for bone repair. Bone Res. 2016;4(1):16050. https://doi.org/10.1038/boneres.2016.50.10.1038/boneres.2016.50 ↗
38. Zhang Y, Jia Y, Li S, Deng Y, Liu H, He N. Genotyping of –765G > C in COX-2 gene based on MNPs and dual-color fluorescence hybridization and its association with risk of gastric cancer in Northern Jiangsu of China. Sci Adv Mater. 2014;6(6):1146–53. https://doi.org/10.1166/sam.2014.1877.10.1166/sam.2014.1877 ↗
39. Elingarami S, Deng Y, Fan J, Zhang Y, He N. NEIL-2 Single nucleotide polymorphism genotyping using single base extension on core–shell Fe3O4@SiO2@Au magnetic nanoparticles and association of the genotypes with gastric cancer risk in Northern Jiangsu (China). Sci Adv Mater. 2014;6(5):899–907. https://doi.org/10.1166/sam.2014.1853.10.1166/sam.2014.1853 ↗
40. Zhang Y, Liu H, Jia Y, Deng Y, Li S, He N. A magnetic nanoparticles-based combination detection of COX-2 and BCL-2 polymorphisms associated with gastric cancer susceptibility. Sci Adv Mater. 2015;7(3):532–9. https://doi.org/10.1166/sam.2015.2130.10.1166/sam.2015.2130 ↗
41. Mou X, Li T, Wang J, Ali Z, Zhang Y, Chen Z, et al. Genetic variation of BCL2 (rs2279115), NEIL2 (rs804270), LTA (rs909253), PSCA (rs2294008) and PLCE1 (rs3765524, rs10509670) genes and their correlation to gastric cancer risk based on universal tagged arrays and Fe3O4 magnetic nanoparticles. J Biomed Nanotechnol. 2015;11(11):2057–66. https://doi.org/10.1166/jbn.2015.2113.10.1166/jbn.2015.2113 ↗
42. Elingarami S, Liu H, Kalinjuma AV, Hu W, Li S, He N. Polymorphisms in NEIL-2, APE-1, CYP2E1 and MDM2 genes are independent predictors of gastric cancer risk in a Northern Jiangsu Population (China). J Nanosci Nanotechnol. 2015;15(7):4815–28. https://doi.org/10.1166/jnn.2015.10028.10.1166/jnn.2015.10028 ↗
43. Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/S0140-6736(20)31288-5.10.1016/S0140-6736(20)31288-5 ↗
44. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79. https://doi.org/10.3322/caac.21657.10.3322/caac.21657 ↗
45. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008. PubMed PMID: 35130500.10.6004/jnccn.2022.0008 ↗
46. Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https://doi.org/10.1186/s13045-023-01451-3.10.1186/s13045-023-01451-3 ↗
47. Ling L-X, Ouyang Y, Hu Y. Research trends on nanomaterials in gastric cancer: a bibliometric analysis from 2004 to 2023. J Nanobiotechnol. 2023;21(1):248. https://doi.org/10.1186/s12951-023-02033-8.10.1186/s12951-023-02033-8 ↗
48. Liu BN, Gao XL, Piao Y. Mapping the intellectual structure and emerging trends for the application of nanomaterials in gastric cancer: a bibliometric study. World J Gastrointest Oncol. 2024;16(5):2181–99. https://doi.org/10.4251/wjgo.v16.i5.2181. PubMed PMID: 38764848; PubMed Central PMCID: PMC11099444.10.4251/wjgo.v16.i5.2181 ↗
49. Ang CY, Tan SY, Zhao Y. Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy. Org Biomol Chem. 2014;12(27):4776 – 806. https://doi.org/10.1039/c4ob00164h. PubMed PMID: 24737243.10.1039/c4ob00164h ↗
50. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193. https://doi.org/10.3389/fmolb.2020.00193. Epub 20200820.10.3389/fmolb.2020.00193 ↗
51. Li R, Liu B, Gao J. The application of nanoparticles in diagnosis and theranostics of gastric cancer. Cancer Lett. 2017;386:123–30. https://doi.org/10.1016/j.canlet.2016.10.032. Epub 20161111.10.1016/j.canlet.2016.10.032 ↗
52. Diep YN, Kim TJ, Cho H, Lee LP. Nanomedicine for advanced cancer immunotherapy. J Control Release. 2022;351:1017–37. https://doi.org/10.1016/j.jconrel.2022.10.004. Epub 20221019.10.1016/j.jconrel.2022.10.004 ↗
53. Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A. bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsystems Nanoengineering. 2024;10(1):113. https://doi.org/10.1038/s41378-024-00743-z.10.1038/s41378-024-00743-z ↗
54. Radulescu DM, Surdu VA, Ficai A, Ficai D, Grumezescu AM, Andronescu E. Green Synthesis of metal and metal oxide nanoparticles: a review of the principles and biomedical applications. Int J Mol Sci. 2023;24(20). Epub 20231020. https://doi.org/10.3390/ijms242015397. PubMed PMID: 37895077; PubMed Central PMCID: PMC10607471.10.3390/ijms242015397 ↗
55. Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Therapy. 2023;8(1):293. https://doi.org/10.1038/s41392-023-01536-y.10.1038/s41392-023-01536-y ↗
56. Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response. 2020;18(3):1559325820936161. Epub 20200710. doi: 10.1177/1559325820936161. PubMed PMID: 32699536; PubMed Central PMCID: PMC7357073.10.1177/1559325820936161 ↗
57. Mukherjee A, Bisht B, Dutta S, Paul MK. Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy. Acta Pharmacol Sin. 2022;43(11):2759–76. https://doi.org/10.1038/s41401-022-00902-w. Epub 20220404.10.1038/s41401-022-00902-w ↗
58. Lin J, Wang X, Ni D, Chen Y, Chen C, Liu Y. Combinational gene therapy toward cancer with nanoplatform: strategies and principles. ACS Mater Au. 2023;3(6):584–99. https://doi.org/10.1021/acsmaterialsau.3c00035. Epub 20230727.10.1021/acsmaterialsau.3c00035 ↗
59. Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y. Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance. Pharmaceutics. 2024;16(12). Epub 20241203. https://doi.org/10.3390/pharmaceutics16121549. PubMed PMID: 39771528; PubMed Central PMCID: PMC11728492.10.3390/pharmaceutics16121549 ↗
60. Xiong J, Han S, Ding S, He J, Zhang H. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep. 2018;39(3):1396–404. https://doi.org/10.3892/or.2018.6201. Epub 20180109.10.3892/or.2018.6201 ↗
61. Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F et al. HER-2-Targeted nanoparticles for breast cancer diagnosis and treatment. Cancers (Basel). 2022;14(10). Epub 20220513. https://doi.org/10.3390/cancers14102424. PubMed PMID: 35626028; PubMed Central PMCID: PMC9139811.10.3390/cancers14102424 ↗
62. Sen P, Saha M, Ghosh SS. Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics. Mater Adv. 2020;1(8):2614–30. https://doi.org/10.1039/d0ma00455c.10.1039/d0ma00455c ↗
63. Mousavi-Kiasary SMS, Senabreh A, Zandi A, Pena R, Cruz F, Adibi A, Hooshmand N. Synergistic cancer therapies enhanced by nanoparticles: advancing nanomedicine through multimodal strategies. Pharmaceutics. 2025;17(6). Epub 20250522. https://doi.org/10.3390/pharmaceutics17060682. PubMed PMID: 40573996; PubMed Central PMCID: PMC12196053.10.3390/pharmaceutics17060682 ↗
64. Turkmen Koc SN, Rezaei Benam S, Aral IP, Shahbazi R, Ulubayram K. Gold nanoparticles-mediated photothermal and photodynamic therapies for cancer. Int J Pharm. 2024;655:124057. https://doi.org/10.1016/j.ijpharm.2024.124057. Epub 20240327.10.1016/j.ijpharm.2024.124057 ↗
65. Yue J, Mei Q, Wang P, Miao P, Dong W-F, Li L. Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy. J Nanobiotechnol. 2022;20(1):181. https://doi.org/10.1186/s12951-022-01388-8.10.1186/s12951-022-01388-8 ↗
66. Ashour AA, Tayeb FJ, Felemban MF, Shafie A. Nanomaterial-based biosensors for cancer diagnosis: trends and innovations (2022–2025). Mikrochim Acta. 2025;192(7):404. Epub 20250604. https://doi.org/10.1007/s00604-025-07276-w. PubMed PMID: 40465004.10.1007/s00604-025-07276-w ↗
67. Lodhi MS, Khan MT, Aftab S, Samra ZQ, Wang H, Wei DQ. A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancer. Cancer Nanotechnol. 2021;12(1):26. https://doi.org/10.1186/s12645-021-00098-4.10.1186/s12645-021-00098-4 ↗
68. Li CH, Chan MH, Chang YC, Hsiao M. Gold nanoparticles as a biosensor for cancer biomarker determination. Molecules. 2023;28(1). Epub 20230102. doi: 10.3390/molecules28010364. PubMed PMID: 36615558; PubMed Central PMCID: PMC9822408.10.3390/molecules28010364 ↗
69. Shao P, Dong D, Huang Y, Wang Y, Pan L, Zhu Q, et al. Aptamer-based functionalized SERS biosensor for rapid and ultrasensitive detection of gastric cancer-related biomarkers. Int J Nanomed. 2023;18:7523–32. https://doi.org/10.2147/ijn.S434854. Epub 20231211.10.2147/ijn.S434854 ↗
70. Ji Z, Li Y, He S, Ju J, Chen Y. Low-dimensional nanomaterials for electrochemical biosensing of gastric cancer biomarkers in whole blood: current trends and future prospects. Mater Today Bio. 2025;33:102033. https://doi.org/10.1016/j.mtbio.2025.102033. Epub 20250701.10.1016/j.mtbio.2025.102033 ↗
71. Chen C, Li J, Hua X, Deng T, Zhang Z. Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers. Front Immunol. 2025;16:1653829. Epub 20250814. doi: 10.3389/fimmu.2025.1653829. PubMed PMID: 40895525; PubMed Central PMCID: PMC12391005.10.3389/fimmu.2025.1653829 ↗
72. Cai T, Liu H, Zhang S, Hu J, Zhang L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. J Nanobiotechnol. 2021;19(1):389. https://doi.org/10.1186/s12951-021-01146-2.10.1186/s12951-021-01146-2 ↗
73. Meng F, Tao H, Mi Y, Yang T, Wang X, Go Y, et al. Nanocluster-mediated photothermia improves eradication efficiency and antibiotic sensitivity of Helicobacter pylori. Cancer Nanotechnol. 2022;13(1):13. https://doi.org/10.1186/s12645-022-00121-2.10.1186/s12645-022-00121-2 ↗
74. Wang S, Ding H, Li L, Zhao R, Chai N. Targeted nanomedicines for the treatment of Helicobacter pylori infection. Mater Today Bio. 2025;32:101820. https://doi.org/10.1016/j.mtbio.2025.101820. Epub 20250430.10.1016/j.mtbio.2025.101820 ↗